Dendreon to close plant and make layoffs as it tackles Provenge slip
This article was originally published in Scrip
Executive Summary
Dendreon will close a manufacturing plant in Morris Plains, New Jersey in the US and cut 600 jobs as it strengthens its sales team in the face of a 2.4% decline in revenue between the first and second quarters of 2012 from its sole product Provenge (sipuleucel-T), an autologous cellular immunotherapy for asymptomatic or minimally symptomatic metastatic castrate-resistant prostate cancer.